产品说明
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles.
应用
Ritonavir may be used as an analytical reference standard for the quantification of the analyte in pharmaceutical formulations using chromatography techniques.
包装
Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
其他说明
Sales restrictions may apply.
基本信息
经验(实验)分子式 | C37H48N6O5S2 |
分子量 | 720.94 |
产品性质
质量水平 | 100 |
等级 | pharmaceutical primary standard |
agency | BP |
形式 | solid |
包装 | pkg of 100 mg |
manufacturer/tradename | BP |
储存条件 | dry at room temperature |
颜色 | off-white |
mp | 122-126 ℃ |
溶解性 | ethanol: soluble isopropanol: soluble methanol: soluble |
密度 | 1.239 g/cm3 at 20 ℃ |
application(s) | pharmaceutical |
运输 | ambient |
储存温度 | 2-8℃ |
InChI | 1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 |
InChI key | NCDNCNXCDXHOMX-XGKFQTDJSA-N |
安全信息
象形图 | |
警示用语: | Warning |
危险声明 | H302 + H312 + H332 |
预防措施声明 | P280 - P301 + P312 + P330 - P302 + P352 + P312 - P304 + P340 + P312 |
危险分类 | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral |
储存分类代码 | 11 - Combustible Solids |
WGK | WGK 3 |
闪点(F) | Not applicable |
闪点(C) | Not applicable |